Covid Vaccine: More than 45.37 Crore doses provided to States/UTs

More than 3.09 Crore balance and unutilized doses still available with States/UTs and private hospitals to be administered

The Union Government is committed to accelerate the pace and expand the scope of COVID-19 vaccination throughout the country. The new phase of universalization of COVID-19 vaccination commenced from 21 June 2021, reports PIB.
The vaccination drive has been ramped up through availability of more vaccines, advance visibility of vaccine availability to States and UTs for enabling better planning by them, and streamlining the vaccine supply chain.
Recovered Cases
Image: Recovered Cases
As part of the nationwide vaccination drive, Government of India has been supporting the States and UTs by providing them COVID Vaccines free of cost. In the new phase of the universalization of the COVID-19 vaccination drive, the Union Government will procure and supply (free of cost) 75% of the vaccines being produced by the vaccine manufacturers in the country to States and UTs.
The vaccination drive has been ramped up through availability of more vaccines, advance visibility of vaccine availability to States and UTs for enabling better planning by them, and streamlining the vaccine supply chain.
More than 45.37 crore (45,37,70,580) vaccine doses have been provided to States/UTs so far, through all sources and a further 59,39,010 doses are in the pipeline. Of this, the total consumption including wastage is 42,28,59,270 doses.
More than 3.09 Cr (3,09,11,310) balance and unutilized COVID Vaccine doses are still available with the States/UTs and private hospitals to be administered.
vaccination  doses
Image: vaccination doses
The new phase of universalization of COVID-19 vaccination has commenced from 21st June, 2021. Out of the people infected since the beginning of the pandemic, 3,05,79,106 people have already recovered from COVID-19 and 35,968 patients have recovered in the last 24 hours. This constitutes an overall recovery rate of 97.35%.



Be the first to start a discussion here. Sign-in to write a comment now!